HUBBARD, Ohio, April 24, 2012 /PRNewswire/ -- A well-respected, independent, third-party laboratory has tested for Tuberculosis (TB) using NanoLogix (PINK SHEETS: NNLX), BNP (BioNanoPore) test kits and achieved the detection of live TB colonies in 4 to 5 days.  Standard culture times for conventional technologies take a minimum of 16 to 21 days to achieve similar results.  In concurrent tests for TB at the same facility, using Nanologix BNF (BioNanoFilter) test kits, Antibody/Antigen TB-specific test results were obtained in 1 hour 30 minutes.  For research and publication purposes, all test results were confirmed with PCR.  Comprehensive results of these independent tests are currently undergoing editing for publication in a major peer-reviewed, scientific journal.

Group B Strep Research Published

Results of an ongoing (status: 340 of 350 patients complete) Group B streptococcus clinical study being conducted at the University of Texas Health Science Center - Houston, using NanoLogix technology, has been published in the April 2012 edition of the Journal of Diagnostic Microbiology and Infectious Disease. The paper is titled, Optimization of a rapid diagnostic test for detection of group B streptococcus from antepartum patients.  Authored by Dr. Jonathan Faro, et al, a full abstract of the paper can be found at  http://www.sciencedirect.com/science/article/pii/S0732889312001071

NanoLogix "Flat Pack" Packaging Method Achieves Milestone With One Year Shelf Life

A major independent research facility is evaluating the shelf life of petri-based technology sealed in NanoLogix patent-pending "Flat-Pack" vacuum packaging.  The results to date demonstrate shelf life of at least one year.  The recommended shelf life for standard non-NanoLogix petri-based products packaged in standard packaging is currently three months. To read the scientific assessment, please visit http://www.nanologix.com/resources.html

New Science Advisory Board Member

NanoLogix welcomes Mark Wheeler, MD to its Science Advisory Board.  Dr. Wheeler brings an extensive medical, investment and business background to the Advisory Board.  For more information about Dr. Wheeler please visit  http://nanologix.com/about/team.html.

First and Second Quarter Business Developments

At the 2012 ASM BioDefense and Emerging Diseases Conference and the Food Safety Summit, NanoLogix received strong interest in its technology from multiple corporate and institutional entities, domestic and foreign. NanoLogix exhibited at both events, which were held in February and April, respectively, in Washington D.C.

In addition to US sales, the company has recently shipped BNP and/or BNF test kits to Europe, India, Turkey and the Middle East.  

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity

For more information visit www.nanologix.com.

Media Contact:
Lisa Ann Pinkerton
408-806-9626
Lisaann@technicacommunications.com

Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
carol@nanologix.com

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

SOURCE NanoLogix, Inc.